Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
tebentafusp (Kimmtrak) (2022 NDA)
imc-f106c (2 trials)
nivolumab (opdivo) (1 trial)
pembrolizumab (keytruda) (2 trials)
relatlimab (Opdualag) (1 trial)
tebentafusp (Kimmtrak) (9 trials)
atezolizumab (Tecentriq) (1 trial)
dacarbazine (dtic-dome) (1 trial)
durvalumab (imfinzi) (1 trial)
imc-c103c (1 trial)
imcnyeso (1 trial)
ipilimumab (yervoy) (1 trial)
tremelimumab (Imjudo) (1 trial)
imc-i109v-101 (1 trial)
Melanoma (Phase 2)
Uveal Neoplasms (Phase 2)
Trials (14 total)
Trial APIs (13 total)